NEW YORK (360Dx) – Startup True Bearing Diagnostics has cemented its plans to launch an RNA-based test for coronary artery disease and is working on collecting the validation evidence it intends to submit to the US Food and Drug Administration for the assay early next year.

The company, founded in 2015, is the fruit of support provided by St. Laurent Institute to encourage what True Bearing CEO Tisha Jepson said has been a variety of projects applying SeqLL's amplification-free sequencing platform to the identification of novel disease signatures.